Skip Navigation LinksHome > January 15, 2014 - Volume 97 - Issue 1 > Crossmatch-Positive Liver Transplantation in Patients Receiv...
Transplantation:
doi: 10.1097/TP.0b013e3182a688c0
Clinical and Translational Research

Crossmatch-Positive Liver Transplantation in Patients Receiving Thymoglobulin-Rituximab Induction

Kubal, Chandrashekhar A.1,5; Mangus, Richard S.1; Saxena, Romil2; Lobashevsky, Andrew3; Higgins, Nancy3; Agarwal, Avinash4; Fridell, Jonathan A.1; Tector, A. Joseph1

Collapse Box

Abstract

Background

Positive crossmatch (CM) in liver transplantation (LT) is associated with worse outcomes. Role of induction immunosuppression in this setting remains to be studied.

Methods

One thousand consecutive LT patients receiving rabbit antithymocyte globulin±rituximab induction were studied. Pretransplantation sera of 55 CM-positive (CM+) patients were tested for C1q-fixing donor-specific antibodies (DSA). Diagnosis of antibody-mediated rejection required presence of diffuse vascular C4d expression on liver biopsies.

Results

CM was positive in 112 (11%) recipients. Antibody-mediated rejection was observed in 3 (0.03%) patients, whereas acute cellular rejection (ACR) occurred in 31 (3%) patients. CM+ status was associated with a higher incidence of ACR (9% in CM+ vs. 2% in CM-negative [CM]; P<0.01) and chronic rejection (4% in CM+ vs. 1% in CM; P<0.01). Graft survival was slightly lower in CM+ patients (at 1 year; 85% in CM+ vs. 89% in CM; P=0.26). Patients with autoimmune hepatitis, primary sclerosing cholangitis, and primary biliary cirrhosis as a group had a tendency toward CM+ status as well as developing ACR. Upon multivariate analysis, CM status was the strongest predictor of ACR (B=1.14; P=0.02). Only half of CM+ patients harbored C1q-fixing DSA. Presence of C1q-fixing DSA was not associated with increased incidence of ACR.

Conclusions

In LT, CM+ status is associated with an increased incidence of acute rejection, chronic rejection, and slightly worse graft survival. With the use of rabbit antithymocyte globulin±rituximab induction, overall low rejection rates can be achieved in CM+ LT.

Copyright © 2013 by Lippincott Williams & Wilkins

Login

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.